A similar study utilizing HDAC6 inhibition in Charcot-Marie-Tooth (CMT) disease showed an improvement in axonal mitochondrial transport, supporting HDAC6 inhibition as a candidate therapeutic for multiple neurodegenerative diseases (d’Ydewalle et al., 2011). Here, HDAC6 is linked to neurodegenerative disease.